Date published: 2025-10-31

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr748 Inhibitors

Olr748 inhibitors are a class of chemical compounds specifically designed to interact with the olfactory receptor 748 (Olr748). These compounds function by binding to the receptor, thereby altering its normal signaling pathway. Olr748 is part of the extensive family of G-protein coupled receptors (GPCRs), which play crucial roles in transducing extracellular signals into intracellular responses. Inhibitors targeting Olr748 are typically small molecules that exhibit high affinity and specificity for the receptor, allowing precise modulation of its activity. The design and synthesis of Olr748 inhibitors involve sophisticated techniques in medicinal chemistry, including structure-activity relationship (SAR) studies, which help in understanding the molecular features critical for binding and activity.

From a structural perspective, Olr748 inhibitors often possess a core framework that enables optimal interaction with the receptor's binding site. This core is usually surrounded by functional groups that enhance the inhibitor's binding affinity and specificity. Advanced computational modeling and crystallography are employed to visualize the receptor's three-dimensional structure, guiding the rational design of these inhibitors. Additionally, synthetic routes to these compounds are carefully optimized to yield high-purity products, facilitating their use in various research applications. The development of Olr748 inhibitors also involves extensive in vitro and in vivo studies to evaluate their efficacy in modulating olfactory signaling. These studies contribute to a deeper understanding of olfactory receptor functions and their broader physiological roles, providing valuable insights into the fundamental mechanisms of sensory perception.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lapatinib

231277-92-2sc-353658
100 mg
$412.00
32
(1)

EGFR and HER2 inhibitor, potentially affecting proteins in associated signaling pathways.

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

CDK4/6 inhibitor, potentially disrupting cell cycle regulation proteins.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

JAK1 and JAK2 inhibitor, potentially affecting proteins in JAK-STAT signaling pathways.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Multi-kinase inhibitor, potentially disrupting proteins in angiogenesis and growth factor signaling pathways.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

HDAC inhibitor, potentially affecting gene expression and associated protein pathways.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

BCR-ABL and Src kinase inhibitor, potentially affecting proteins in leukemia signaling pathways.

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$74.00
$119.00
33
(1)

EGFR inhibitor, potentially affecting proteins in the EGFR signaling pathway.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

EGFR inhibitor, potentially disrupting proteins in the EGFR signaling pathway.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

BCR-ABL, c-Kit, and PDGFR inhibitor, potentially affecting proteins in associated signaling pathways.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$205.00
$405.00
9
(1)

BCR-ABL inhibitor, potentially disrupting proteins in leukemia signaling pathways.